Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

34.28 +0.06 (+0.18%)
Streaming Delayed Price Updated: 9:52 AM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 83,383
Open 34.63
Bid (Size) 34.25 (300)
Ask (Size) 34.28 (400)
Prev. Close 34.22
Today's Range 34.08 - 34.66
52wk Range 23.62 - 35.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Genmab (GMAB) Q2 2026 Earnings Call Transcript ↗
Revenue guidance raised to $4.3B–$4.5B as non-DARZALEX products drive half of growth. 
Via The Motley Fool
Topics Earnings
News headline image
Genmab A/S Q2 Earnings Call Highlights ↗
Genmab A/S (NASDAQ:GMAB) reported first-half 2026 revenue growth of 25% year over year and raised its full-year financial outlook, citing continued momentum from DARZALEX, EPKINLY and the broader... 
Via MarketBeat
Topics Earnings

Performance

YTD
+7.7%
+7.7%
1 Month
+19.5%
+19.5%
3 Month
+43.6%
+43.6%
6 Month
+21.6%
+21.6%
1 Year
+32.4%
+32.4%

More News

Read More
Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup ↗
Via Chartmill
News headline image
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S and AbbVie
Via Business Wire
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment ↗
Via Chartmill
Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗
Via Chartmill
News headline image
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
From Genmab
Via Business Wire
News headline image
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
From Genmab A/S
Via Business Wire
News headline image
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
From Genmab A/S
Via Business Wire
GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗
Via Chartmill
GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗
Via Chartmill
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Via The Motley Fool
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
Via MarketMinute
Topics ETFs Economy Intellectual Property
GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals ↗
Via Chartmill
News headline image
My Top 4 Stocks to Buy in Early 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗
Via Chartmill
News headline image
Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗
Via Stocktwits
News headline image
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
Why Are Investors Paying Attention To Genmab Stock? ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
From Genmab A/S
Via Business Wire
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
Via Stocktwits
Topics Supply Chain

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?
Yes, Genmab A/S - American Depositary Shares is publicly traded.
What exchange does Genmab A/S - American Depositary Shares trade on?
Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Genmab A/S - American Depositary Shares?
The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market
What is the current price of Genmab A/S - American Depositary Shares?
The current price of Genmab A/S - American Depositary Shares is 34.28
When was Genmab A/S - American Depositary Shares last traded?
The last trade of Genmab A/S - American Depositary Shares was at 09/03/26 09:52 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>